ArticleTrials2022

Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.

Hugh Gallagher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.